Anaphylaxis is a severe life-threatening reaction following exposure to an antigen. Its incidence is progressively increasing in the general population over years, accompanied with an increased number of hospitalizations. Although rare, this condition is often associated with a significant morbidity and mortality. The mortality rate has been recently estimated at 0.84 (95% CI, 0.79 to 0.88) per million per year in the French adult population. Age, chronic medication and cardiac or pulmonary comorbidities have been reported to increase the risk of a severe reaction. Obesity, age and cardiovascular comorbidities have been identified as risk factors for fatal anaphylaxis. However, the risk factors for death after ICU admission have not been elucidated yet.
Study Type
OBSERVATIONAL
Enrollment
339
University Hospital of Nancy
Nancy, France
University Hospital of Strasbourg
Strasbourg, France
In-ICU mortality
The number of participants deceased within ICU hospitalisation
Time frame: Day 30
Volume of fluid administered
The volume of fluid administered during priori to and during ICU stay, in millilitres will be noted
Time frame: Day 30
Amount of epinephrine
Quantity of epinephrine administered during ICU stay
Time frame: Day 30
Amount of norepinephrine
Quantity of norepinephrine administered during ICU stay
Time frame: Day 30
Number and severity of organ failure
The severity of organ failure will be assessed with the SOFA score
Time frame: Day 30
Extracorporeal life support requirement
The number of participants that required ECMO V/V or A/V
Time frame: Day 30
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.